Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies

Toshiki Tezuka, Keisuke Takahata, Morinobu Seki, Hajime Tabuchi, Yuki Momota, Mika Shiraiwa, Natsumi Suzuki, Ayaka Morimoto, Tadaki Nakahara, Yu Iwabuchi, Eisuke Miura, Yasuharu Yamamoto, Yasunori Sano, Kei Funaki, Bun Yamagata, Ryo Ueda, Takahito Yoshizaki, Kyoko Mashima, Mamoru Shibata, Munenori OyamaKensuke Okada, Masahito Kubota, Hajime Okita, Masaki Takao, Masahiro Jinzaki, Jin Nakahara, Masaru Mimura, Daisuke Ito

研究成果: Article査読

15 被引用数 (Scopus)


Tau aggregates represent a key pathologic feature of Alzheimer's disease and other neurodegenerative diseases. Recently, PET probes have been developed for in vivo detection of tau accumulation; however, they are limited because of off-target binding and a reduced ability to detect tau in non-Alzheimer's disease tauopathies. The novel tau PET tracer, [18F]PI-2620, has a high binding affinity and specificity for aggregated tau; therefore, it was hypothesized to have desirable properties for the visualization of tau accumulation in Alzheimer's disease and non-Alzheimer's disease tauopathies. To assess the ability of [18F]PI-2620 to detect regional tau burden in non-Alzheimer's disease tauopathies compared with Alzheimer's disease, patients with progressive supranuclear palsy (n 3), corticobasal syndrome (n 2), corticobasal degeneration (n 1) or Alzheimer's disease (n 8), and healthy controls (n 7) were recruited. All participants underwent MRI, amyloid b assessment and [18F]PI-2620 PET (Image acquisition at 60- 90 min post-injection). Cortical and subcortical tau accumulations were assessed by calculating standardized uptake value ratios using [18F]PI-2620 PET. For pathologic validation, tau pathology was assessed using tau immunohistochemistry and compared with [18F]PI-2620 retention in an autopsied case of corticobasal degeneration. In Alzheimer's disease, focal retention of [18F]PI- 2620 was evident in the temporal and parietal lobes, precuneus, and cingulate cortex. Standardized uptake value ratio analyses revealed that patients with non-Alzheimer's disease tauopathies had elevated [18F]PI-2620 uptake only in the globus pallidus, as compared to patients with Alzheimer's disease, but not healthy controls. A head-to-head comparison of [18F]PI-2620 and [18F]PMPBB3, another tau PET probe for possibly visualizing the four-repeat tau pathogenesis in non-Alzheimer's disease, revealed different retention patterns in one subject with progressive supranuclear palsy. Imaging-pathology correlation analysis of the autopsied patient with corticobasal degeneration revealed no significant correlation between [18F]PI-2620 retention in vivo. High [18F]PI- 2620 uptake at 60-90 min post-injection in the globus pallidus may be a sign of neurodegeneration in four-repeat tauopathy, but not necessarily practical for diagnosis of non-Alzheimer's disease tauopathies. Collectively, this tracer is a promising tool to detect Alzheimer's disease-tau aggregation. However, late acquisition PET images of [18F]PI-2620 may have limited utility for reliable detection of four-repeat tauopathy because of lack of correlation between post-mortem tau pathology and different retention pattern than the non-Alzheimer's disease-detectable tau radiotracer, [18F]PM-PBB3. A recent study reported that [18F]PI-2620 tracer kinetics curves in four-repeat tauopathies peak earlier (within 30 min) than Alzheimer's disease; therefore, further studies are needed to determine appropriate PET acquisition times that depend on the respective interest regions and diseases.

ジャーナルBrain Communications
出版ステータスPublished - 2021

ASJC Scopus subject areas

  • 精神医学および精神衛生
  • 生物学的精神医学
  • 細胞および分子神経科学
  • 神経学


「Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。